7-keto-DHEA

7-Keto-DHEA (7-Ketodehydroepiandrosterone)

1. Identity: Chemical Names, Natural Source, and Commercial Forms

Nomenclature

7-Ketodehydroepiandrosterone (7-keto-DHEA, 7-oxo-DHEA), also known as 7-oxoprasterone, is a steroid prohormone produced by metabolism of the prohormone dehydroepiandrosterone (DHEA). Its systematic chemical name is 3-acetyl-7-oxo-dehydroepiandrosterone, and it is also formally designated as 3β-hydroxy-androst-5-ene-7,17-dione, a compound included in Section S1 of the World Anti-Doping Agency (WADA) List of Prohibited Substances.

Natural Occurrence and Endogenous Synthesis

7-Keto is called 3-acetyl-7-oxo-dehydroepiandrosterone, a naturally occurring metabolite primarily produced in the adrenal glands, skin and, to some degree, in the brain. 7-Keto-DHEA, a metabolite of the hormone dehydroepiandrosterone (DHEA), is naturally produced in the body. It is synthesized through a two-step enzymatic process involving cytochrome P450 7B1 (CYP7B1) and 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD 1), which converts DHEA into 7-keto-DHEA via intermediary compounds. More specifically, DHEA is hydroxylated at the 7α position, and this derivative is oxidized by 11β-hydroxysteroid dehydrogenase to form 7-keto DHEA. The latter is reduced by the same dehydrogenase to form 7β-hydroxy DHEA.

In humans, 7-oxo-DHEA occurs physiologically at levels that parallel DHEA, peaking during young adulthood (around 20–30 years) and progressively declining with age, often to 10–20% of peak values by late life. This age-related decrease mirrors broader adrenal androgen patterns and has been quantified in serum and urine across lifespan studies. Just like DHEA, 7-Keto peaks in the early 20s and declines over time to about 50% by age 50.

The parent compound, DHEA, is itself produced in significant quantities by the adrenal cortex. Synthesis of dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS) is by the zona reticularis of the adrenal gland. Levels decline dramatically after birth, gradually increasing again during adrenarche to reach peak levels in young adulthood. Unlike the other major steroids secreted by the adrenal, serum DHEA(S) levels then follow a progressive age-related decline.

Key Structural Distinction from DHEA

7-Keto-DHEA is not directly converted to testosterone or estrogen by the human body. Unlike DHEA, 7-keto DHEA has no androgenic activity, as it is not converted to androgen, and because substitution at the 7 position prevents aromatization, it also cannot be converted to estrogen. This structural feature — the ketone group at carbon-7 — is the defining difference from its parent compound and the primary rationale for its commercial development as a supplement.

Commercial Forms and Preparations

The acetylated version of 7-keto-DHEA, designated as 3-acetyl-7-oxo-dehydroepiandrosterone, or the branded ingredient 7-Keto (licensed by Humanetics Corp.), has been the subject of multiple human randomized, placebo-controlled, double-blind studies. The acetylated compound is less susceptible to oxidation during the manufacturing process relative to 7-keto-DHEA and is rapidly converted to 7-keto-DHEA upon ingestion.

7-Keto-DHEA emerged as a commercial dietary supplement in the late 1990s, developed by Humanetics Corporation, which submitted a successful New Dietary Ingredient notification to the U.S. Food and Drug Administration in 1997. As an endogenous "metabolite," 7-keto-DHEA meets the U.S. regulatory definition of a dietary ingredient as defined by DSHEA. In 1997, General Nutrition Corp. (GNC) filed a New Dietary Ingredient (NDI) notification, on behalf of GNC as well as Humanetics Corp., for the use of 7-Keto. The FDA filed this notification without comment. The intended dose in this notification was 25 mg up to two times per day. In 2002, Perrigo Co. filed another NDI notification for 7-Keto, with a suggested dose of 100 mg up to two times daily. FDA also filed this notification without comment.

7-Keto-DHEA is commercially available in oral capsule and tablet forms, and also as a topical gel preparation. While 7-Keto does not affect hormone levels in the body when taken as an oral supplement, it may influence them if applied to the skin as a gel. Several studies have shown that when applied to the skin, 7-Keto can affect sex hormones, cholesterol and thyroid function in men.

2. Historical and Scientific Discovery Context

Unlike many botanical supplements with centuries of traditional use, 7-keto-DHEA has no documented history of traditional herbal or folk medicinal use. It is an endogenous steroid metabolite that was identified and characterized through modern biochemical research, not through ethnomedical tradition.

Research on 7-keto DHEA has been conducted for over ten years by Professor Henry A. Lardy and his team at the Institute for Enzyme Research at the University of Wisconsin. Based on this research, Professor Lardy received nine patents covering the uses of 7-Keto DHEA to boost and modulate the immune system, help treat Alzheimer's disease, and promote weight loss.

By the 1990s, investigations highlighted its distinct role in steroid metabolism, including induction of thermogenic enzymes in rat liver, as shown by Lardy et al., who identified 7-oxo-DHEA and related "ergosteroids" as biologically active without hormonal conversion. These milestones established 7-oxo-DHEA's position beyond a mere inert byproduct.

Humanetics Corp. holds the patent for the use of 7-Keto for promoting weight maintenance or weight loss by modulating the basal metabolic rate, among other uses. Humanetics Corp., or companies who have established licensing rights with Humanetics Corp., have sponsored most of the published human clinical trials on the ingredient. This commercial conflict of interest is a material limitation in evaluating the existing clinical evidence base.

3. Key Active Constituents and Mechanisms of Action

Thermogenic Enzyme Induction

The primary proposed mechanism of action for 7-keto-DHEA centers on thermogenesis. Thermogenic and anti-adipogenic effects of 7-keto-DHEA and its metabolites have been identified, although are not fully understood. These compounds are thought to stimulate thermogenesis by enhancing mitochondrial function, similarly to thyroid hormone. Likewise, 7-keto-DHEA has demonstrated the ability to enhance the production of thermogenic enzymes within liver cells, including G-3-P dehydrogenase and malic enzyme.

Both thyroid hormone (thyroxine) and 7-oxo-DHEA induce the formation of liver mitochondrial glycerol-3-phosphate dehydrogenase (G3PD) and malic enzyme, suggesting a shared thermogenic pathway. When fed to rats, each of the latter three steroids induce the formation of two thermogenic enzymes in the liver. Animal work further showed that activity is retained in steroids that are reduced to the corresponding 17β-hydroxy derivative, or hydroxylated at 7α or 7β, and is considerably enhanced when the 17-hydroxy or 17-carbonyl steroid is converted to the 7-oxo derivative. Several derivatives of DHEA did not induce the thermogenic enzymes whereas the corresponding 7-oxo compounds did.

Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD 1)

A second proposed mechanism involves glucocorticoid regulation. Another potential mechanism involves the enzyme 11β-HSD 1, which is responsible for converting cortisone into active cortisol; high levels of cortisol are linked to insulin resistance and obesity. It is proposed that 7-Keto-DHEA may regulate cortisol activity by competitively inhibiting 11β-HSD 1, thereby promoting the production of 7β-OH-DHEA instead of active glucocorticoids. This action might counteract the glucocorticoids' effect of reducing uncoupling proteins — proteins that allow protons to flow into the mitochondrial matrix without generating ATP, thus converting energy into heat.

Thyroid Hormone Modulation

7-Keto DHEA may also support healthy T3 levels without negatively impacting overall thyroid function. In one key clinical trial, weight loss in the 7-Keto group was almost three times the weight loss in the placebo group. Subjects in the 7-Keto group also experienced a statistically significant increase in triiodothyronine (T3) thyroid hormone compared to placebo, although levels were still considered within the normal range. However, subsequent studies have not uniformly replicated this thyroid effect (see Safety section below).

Non-Conversion to Sex Hormones

7-Keto-DHEA is not directly converted to testosterone or estrogen by the human body. Isotope-ratio mass spectrometry (IRMS) analysis confirmed this: the analysis by IRMS confirmed that there is no formation of DHEA from 7-keto-DHEA. This distinguishes it pharmacologically from DHEA itself, which can serve as a precursor to both androgens and estrogens.

4. Scientific Evidence by Area of Use

4.1 Body Weight and Obesity

Overview of the Evidence Base

In a 2023 systematic review, a total of 4 out of 686 studies were included. They all held a low risk of bias. Half of them showed a significant reduction in body weight. One study found a decrease in body fat percentage and another one reported a decrease in BMI. Two studies stated an increase in resting metabolic rate. The systematic review's authors noted that three of the four research papers were led by the same author, representing a notable limitation regarding independent replication. Currently available clinical studies are giving mixed answers regarding 7-keto-DHEA and weight loss. Further studies are encouraged before any therapeutical use can be recommended.

Kalman et al. (2000) — Randomized Controlled Trial

The foundational clinical trial, by Kalman DS, Colker CM, Swain MA, Torina GC, and Shi Q, was a randomized, double-blind, placebo-controlled study of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy overweight adults, published in Current Therapeutic Research, 2000; 61(7):435–442. Data from that trial reported that 7-keto DHEA supplementation (200 mg/d) during 8 weeks of training promoted a greater loss in body mass and fat mass while increasing T3, while observing no significant effects on thyroid stimulating hormone (TSH) or T4.

Zenk et al. (2002) — Randomized Controlled Trial ("7-Keto Naturalean")

A natural metabolite of dehydroepiandrosterone (DHEA), 3-acetyl-7-oxo-dehydroepiandrosterone (7-oxo-DHEA), was assessed in a prospective, randomized, double-blind, placebo-controlled trial. Healthy, overweight adults were given 7-Keto Naturalean (200 mg/d) or a placebo of maltodextrin and followed a calorie-restricted diet (105 kJ/kg) and an exercise program for 8 weeks. Body weight, body composition (by bioelectric impedance), and BMR (by indirect calorimetry) were measured at baseline, week 4, and week 8. In this study, 33 overweight adults received 7-Keto DHEA supplements (200 mg/day) for 8 weeks. 7-keto, along with diet and exercise, reduced weight more than diet and exercise alone with no adverse effects. This study tested a multi-ingredient formulation (including l-tyrosine, asparagus root extract, and other co-ingredients), which limits the ability to attribute the effects solely to 7-keto-DHEA.

Zenk et al. (2007) — Randomized Controlled Crossover Trial

In a 2007 randomized, double-blind, placebo-controlled crossover trial with 40 overweight adults, 200 mg/day of 7-keto-DHEA for 7 days (repeated over three periods with washouts) resulted in a modest 1.43% increase in RMR (P=0.001) compared to baseline, while placebo showed no significant change; no notable effects on body weight or fat were observed over the short duration. More recent data has shown that 7-keto DHEA supplementation can increase RMR and blunt the decrease in RMR associated with 8 weeks of restricted dieting.

Overall Assessment

The benefits of 7-keto-DHEA supplementation are not definitively established. The health claims on potential weight loss benefits are not supported by solid evidence. The current evidence is mixed and limited by factors such as small sample sizes, short study durations, and a lack of diversity in the study populations. Additional human intervention trials involving 7-keto-DHEA (particularly as a monotherapy) are warranted to substantiate the efficacy of this ingredient for weight management in humans, as well as provide a larger understanding of its vast effects in the body. The current research, however, does support a thermogenic effect of 7-keto-DHEA.

4.2 Immune Function

7-Keto is known to have beneficial effects on immune function. A four-week study of 7-Keto supplementation improved immune function in elderly men and women. In the study, the group given 100 mg of 7-Keto twice daily had a significant decrease in immune suppressor cells and a significant increase in immune helper cells. There were also reductions in diastolic blood pressure and an increase in neutrophils. This study was presented at the Federation of American Societies for Experimental Biology (FASEB) meeting in 2004 (Zenk JL, Kuskowski MA), and has not been published in a full peer-reviewed journal article, which limits its evidentiary weight.

Additionally, supplementation with 7-Keto-DHEA for one month in healthy adults improved T-cell mediated immune parameters compared to placebo, addressing age-related declines in cellular immunity. A 2025 preclinical study further suggested its potential as an adjunctive therapy for pulmonary tuberculosis, demonstrating bacteriostatic effects against M. tuberculosis and moderation of lung injury in mouse models. The tuberculosis finding is from animal research and does not constitute clinical evidence in humans.

Overall, the immune evidence for 7-keto-DHEA in humans is limited to small, short-duration studies, some of which have not been published in full peer-reviewed format, and must be considered preliminary.

4.3 Post-Traumatic Stress Disorder (PTSD) and Psychiatric Conditions

Research has explored methods of treating symptoms of psychiatric disorders such as stress disorders, anxiety disorders, and depression using the DHEA metabolite 3-acetyl-7-oxo-dehydroepiandrosterone (7-keto DHEA).

In one study of 5 women with treatment-resistant PTSD, 7-keto DHEA (25–150 mg/day) rapidly improved PTSD symptoms. Despite the promising initial findings, much more research is required. Specifically, these case reports concerned 5 women with severe chronic PTSD resulting from severe early abuse who continued to be highly symptomatic despite receiving extensive psychotherapy and years of psychopharmacologic treatment. All 5 of these treatment-resistant patients experienced a rapid and substantial reduction in their trauma and affective symptoms after starting on treatment with 7-keto DHEA. The improvements in these symptoms not only were subjective and objective, but also manifested in significant and rapid benefits in vocational and interpersonal functioning.

The choice of 7-keto DHEA over DHEA was due to its non-aromatizable nature and potentially superior anti-glucocorticoid properties. This form of DHEA provided rapid, noticeable improvements in PTSD symptoms, suggesting its potential for larger, more rigorous clinical trials.

Ronald Zenk, founder and director of Minneapolis-based Humanetics Pharmaceuticals, described 7-Keto as "a natural compound that has been shown in previous trials to block the negative effects of cortisol" and noted case studies that "suggest that adding 7-Keto to existing treatment regimens may be beneficial in relieving some of the symptoms associated with PTSD." A registered VA clinical trial (NCT01861847) for 7-Keto DHEA for the Treatment of PTSD was completed in 2014, but published peer-reviewed outcome data from this trial are not yet available in the searchable literature at the time of this writing.

The psychiatric evidence base for 7-keto-DHEA remains at a very early, exploratory stage. The only human data consist of a small uncontrolled case series. No randomized controlled trials with published results are available in this indication.

4.4 Memory and Cognitive Function

In animal studies, scientists observed the potential of 7-Keto to improve memory in both young and old mice with memory impairment. The effect was much stronger in young mice, in which 7-Keto completely reversed memory loss. 7-oxo-DHEA was reported to be far more effective in enhancing memory in old mice than DHEA.

The DHEA metabolite 7-keto DHEA appears to have benefits as a natural antiglucocorticoid and to improve symptoms of depression, anxiety, and trauma, and improve memory and cognitive functioning, according to patent documentation, though this characterization draws on the same limited case-series evidence.

No randomized controlled trials specifically investigating cognitive outcomes in human subjects have been published. All memory-related evidence is currently limited to animal models, and the translation of these findings to humans remains undemonstrated.

4.5 Physical Performance and Body Composition

In one study, 33 overweight adults received 7-Keto DHEA supplements (200 mg/day) for 8 weeks, with outcomes extending to body composition. In a study of 40 subjects, 7-keto was used both alone and in combination with other supplements (green tea extract, vitamin C, chromium, and vitamin D3). Both options increased the metabolic rate.

Supplements containing 7-keto-DHEA are sometimes used to increase physical performance and improve weight loss. However, very little research has been done to study this chemical, and its safety and benefits are not well defined. The evidence for athletic performance enhancement specifically remains weak, with no dedicated randomized controlled trials focusing on performance endpoints in athletes.

5. Body Systems and Health Areas of Association

• Metabolic / Endocrine System: The most-studied application. Proposed effects on resting metabolic rate (RMR), thermogenesis, and body fat via upregulation of hepatic thermogenic enzymes and possible 11β-HSD 1 inhibition.
• Immune System: Preliminary human and animal data suggest modulation of T-cell subsets (helper vs. suppressor cells) and neutrophil counts in elderly subjects, suggesting age-related immune support.
• Central Nervous System / Neuropsychiatric: Animal memory studies and a small human PTSD case series suggest neurosteroid-like anti-glucocorticoid activity. A VA-sponsored PTSD trial was completed but peer-reviewed publication of results has not been confirmed.
• Thyroid System: Some, but not all, clinical trials have observed increases in serum T3 within normal range during 7-keto-DHEA supplementation, implicating a possible effect on thyroid hormone metabolism.
• Adrenal / Glucocorticoid Axis: The DHEA metabolite 7-keto DHEA appears to have benefits as a natural antiglucocorticoid and to improve symptoms of depression, anxiety, and trauma.
• Dermatological (Topical Use): Patent literature has explored 7-keto-DHEA and its hydroxylated analogs for topical anti-aging skin applications, including promoting fibroblast proliferation and modulating collagen content, primarily in animal models.

6. Dosage Forms and Doses Reported in Studies

The following doses are reported directly from the sources cited and are not recommendations:

• The intended dose in the 1997 NDI notification was 25 mg up to two times per day.
• In the 2002 NDI notification by Perrigo Co., the suggested dose was 100 mg up to two times daily.
• The Kalman et al. (2000) randomized, double-blind, placebo-controlled study used 3-acetyl-7-oxo-dehydroepiandrosterone in healthy overweight adults at a dose consistent with 200 mg/day over 8 weeks (published in Curr Ther Res, 2000).
• The Zenk et al. (2002) trial administered 200 mg/d of 7-Keto Naturalean (containing 7-oxo-DHEA along with other co-ingredients) to overweight adults following a calorie-restricted diet and exercise program for 8 weeks.
• The Zenk et al. (2007) crossover trial used 200 mg/day of 7-keto-DHEA for 7 days (repeated over three periods with washouts) in 40 overweight adults.
• In the immune function study in elderly subjects, the group given 100 mg of 7-Keto twice daily showed immune changes over four weeks.
• In the PTSD case series in 5 women, 7-keto DHEA was administered at doses ranging from 25 to 150 mg/day.
• In a human escalating-dose safety study, no adverse treatment-related effects were seen in adult men given 200 mg/day (100 mg twice daily) of 7-Keto for 28 days.

7. Safety Considerations and Interactions

General Tolerability

The current evidence is mixed and limited by factors such as small sample sizes, short study durations, and a lack of diversity in the study populations. The safety profile of 7-keto-DHEA appears to be generally well-tolerated with a low side-effect profile, but changes in blood hormone parameters have been reported. Given these uncertainties, the potential benefits and safety of 7-keto-DHEA, particularly with long-term use, are not established.

A safety study in humans has shown that 7-KETO did not raise estrogen or testosterone levels or produce any other negative effects at levels up to 200 mg per day for eight weeks. Short-term animal studies also revealed no adverse effects with large amounts of 7-KETO. However, the long-term safety of 7-KETO for humans has not been demonstrated, and, because it is chemically related to steroid hormones, the potential for adverse effects must be considered.

The human safety studies found no significant changes in vital signs (systolic and diastolic blood pressure, pulse rate, temperature), liver and renal function, hematological profile (including blood sugar, testosterone, and estradiol levels), or in mental or emotional functioning.

Preclinical Toxicology Data

A summary of toxicology data performed on 7-Keto was included in the 1997 NDI notification. This included a negative mutagenicity (AMES) study and an acute oral gavage study in rats indicating a no-adverse-effect level of 2000 mg/kg. Oral doses of 140 mg/kg for 28 days and 500 mg/kg for 7 days were also found to be nontoxic in Rhesus monkeys. No serious adverse events have been reported in any of the human clinical trials on 7-Keto.

Thyroid Hormone Effects

The increase in T3 levels resulting from taking 7-KETO could, in theory, produce adverse effects on the heart or promote bone loss. However, T3 elevations observed in clinical trials remained within the normal reference range. Furthermore, Kalman et al. reported an increase in triiodothyronine (T3) within the normal range; however, the two newer studies observed no such increase in T3 levels, indicating this effect is not consistently replicated.

Route-of-Administration Differences: Oral vs. Topical

7-keto DHEA is produced from DHEA but is not converted to steroid hormones when taken orally. However, when used on the skin, it has been shown to affect hormone levels in men. When applied as a topical gel, 7-keto-DHEA may influence hormone levels, particularly in men, potentially affecting sex hormones, cholesterol, and thyroid function. The effects on women remain unclear.

Mild Adverse Effects

Studies show that 7-keto-DHEA was well tolerated in normal healthy men at doses up to 200 mg/d for up to 8 weeks, although it might cause mild side effects such as nausea, dizziness, or low blood pressure in some people.

Prohibited Status in Sport

7-keto-DHEA (3β-hydroxy-androst-5-ene-7,17-dione) is included in section S1 of the World Anti-Doping Agency (WADA) List of Prohibited Substances. The detection of its misuse in sports needs special attention, since it is naturally present in urine samples. Analytical complications are significant: 7-keto-DHEA metabolism in humans for anti-doping purposes was studied and unexpected results were found. This could lead to a misinterpretation of the data, depending on the procedure applied and the analytical instrumentation used. Athletes subject to anti-doping controls should be aware that 7-keto-DHEA is prohibited by the World Anti-Doping Agency (WADA) for use by athletes, whether they are in or out of competition.

FDA and Regulatory Status

The US Food and Drug Administration (FDA) has not added 7-keto-DHEA to the list of bulk drug substances due to a lack of clinical evidence regarding its safety and efficacy. As an endogenous "metabolite," 7-keto-DHEA meets the U.S. regulatory definition of a dietary ingredient as defined by DSHEA, allowing it to be sold as a dietary supplement without pre-market approval.

Populations Without Established Safety Data

Pregnant and breastfeeding women are advised to refrain from using 7-Keto-DHEA due to insufficient research on its safety during these periods. Given these uncertainties, the potential benefits and safety of 7-keto-DHEA, particularly with long-term use, are not established.

8. Characterization of Overall Evidence Strength

The body of clinical evidence for 7-keto-DHEA is small, concentrated in a narrow group of researchers with commercial affiliations, and limited to short-term studies of modest sample sizes. While the weight loss ability of 7-keto-DHEA is highly promoted commercially, there is limited academic literature about 7-keto-DHEA in terms of weight loss. In the 2023 systematic review, 4 out of 686 papers retrieved from the literature search were eligible, and three research papers were led by the same author. No serious adverse effects were reported, but various possible mechanisms in favor of weight loss are discussed; with the evidence currently available, no clear answer can be given regarding 7-keto-DHEA and weight loss. Further studies need to be conducted to clarify the efficacy and safety of this drug before it can be recommended for therapeutic use.

For immune function, PTSD, and cognitive outcomes, the evidence is limited to animal studies, in vitro experiments, a single small uncontrolled case series (PTSD), and one conference presentation (immune function). These cannot support clinical conclusions. 7-Keto-DHEA is marketed to be more effective than DHEA for inducing heat production (thermogenesis) to be used in weight loss, because dieting is usually accompanied by reduced resting metabolic rate. Still, these claimed benefits are not supported by solid evidence.

References

• Jeyaprakash N, Maeder S, Janka H, Stute P. A systematic review of the impact of 7-keto-DHEA on body weight. Archives of Gynecology and Obstetrics. PMC/PubMed Central, 2023.
• Ventura M, et al. 7-keto-DHEA metabolism in humans. Pitfalls in interpreting the analytical results in the antidoping field. PubMed, 2019.
• 7-Keto-DHEA — Wikipedia.
• Zenk JL, Helmer T, Kassen L, Kuskowski M. The effect of 7-Keto Naturalean on weight loss: A randomized, double-blind, placebo-controlled trial. Current Therapeutic Research, 2002. ScienceDirect.
• Kalman DS, Colker CM, Swain MA, Torina GC, Shi Q. A randomized, double-blind, placebo-controlled study of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy overweight adults. Curr Ther Res 61(7):435–442, 2000. ResearchGate.
• Ingredient Spotlight: 7-Keto-DHEA, Raspberry Ketones. Nutritional Outlook.
• 7-Keto DHEA — Health Information Library. PeaceHealth / TraceGains.
• 7-Keto DHEA Biomarker Reference. Rupa Health.
• US Patent 8,124,598 — 7-keto DHEA for Psychiatric Use. USPTO.
• WADA. DHEA, 7-keto-DHEA and Arimistane: precursors or metabolites. Is IRMS necessary? World Anti-Doping Agency.
• NCT01861847: 7-Keto DHEA for the Treatment of PTSD. ClinicalTrials.gov.
• Natural supplement put to test for PTSD. VA Research Currents, Fall 2013.
• Gurnell EM, et al. Long-Term DHEA Replacement in Primary Adrenal Insufficiency: A Randomized, Controlled Trial. PMC, 2008.
• 7-Keto DHEA Benefits, Side Effects, Dosage & Reviews. SelfDecode Supplements.
• 7-Keto-DHEA — Grokipedia.
• DHEA Deficiency. Thyroid UK.
• Henry A. Lardy — Publications. ScienceDirect.